Assessment of Voiding After Sling (AVAS)

February 18, 2014 updated by: The Cleveland Clinic

Assessment of Voiding After Sling (AVAS): A Randomized Trial of Two Methods of Post-operative Catheter Management After Midurethral Sling for Female Stress Urinary Incontinence

The purpose of this study is to compare the incidence of catheterization from discharge to 6 weeks postoperatively when using two methods of post-operative voiding evaluation after a mid-urethral sling procedure. The investigators' results may lead to a decreased use of indwelling catheters and their associated morbidity after outpatient sling surgery.

Study Overview

Status

Completed

Detailed Description

Minimally invasive slings have demonstrated similar efficacy to earlier abdominal anti-incontinence procedures, but offer the benefit of shorter operating times, less voiding dysfunction, lower morbidity and are usually done as an outpatient procedure. Despite the advantages, about 35% of patients are discharged home with indwelling catheters. Indwelling catheters are bothersome for patients, costly to the healthcare system and are a source of significant morbidity. The challenge for pelvic surgeons performing anti-incontinence procedures is avoiding postoperative urinary retention while minimizing the use of catheters and their associated risks. A commonly described backfill-assisted voiding trial is used as a means of evaluating bladder function postoperatively. This method uses a low post-void residual as a specific criterion for discharge without a catheter. However, the validity of this method has never been critically evaluated. Our recent observational study suggests that patients may be safely discharged without a catheter after a midurethral sling procedure based on their subjective assessment of the force of stream. Our proposed study expands on this pilot data using a randomized trial to evaluate two methods of post-operative voiding evaluation. The results may lead to a decreased use of indwelling catheters and their associated morbidity after outpatient sling surgery.

Study Type

Interventional

Enrollment (Actual)

105

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Beachwood, Ohio, United States, 44122
        • Cleveland Clinic Beachwood
      • Mayfield Heights, Ohio, United States, 44124
        • Cleveland Clinic Hillcrest Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 81 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Enrollment:

All patients,18-81 year old, undergoing an outpatient midurethral sling surgery will be screened for participation in the study at the preoperative visit.

Exclusion:

  1. Women undergoing concomitant urinary tract or pelvic reconstructive procedures
  2. Women with pelvic organ prolapse beyond the hymen
  3. Women who have undergone a different or same procedure for urinary incontinence in the past
  4. Women with neurological conditions, such as multiple sclerosis, spinal cord injury/pathology
  5. Cases complicated by a cystotomy or other complication necessitating postoperative catheterization
  6. Non-English speakers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard Voiding Trial
Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
Experimental: Force of Stream Voiding Trial
Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Catheterization Rate
Time Frame: Surgery to 6-weeks post-operatively

The incidence of postoperative catheterization (total catheterization) at any point from discharge after surgery to 6 weeks postoperatively.

The incidence of being discharged with an indwelling catheter will be gathered from PACU records. The information regarding catheterization after that point will be captured via the electronic medical records or patient questionnaires (at 2 days, 1 week, and 6 week follow-up).

Surgery to 6-weeks post-operatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective assessment of Force of Stream (FOS).
Time Frame: 30 minutes to 2 hours in recovery room
Using VAS, the subject compares the post-operative FOS with the pre-operative FOS on a scale of 0-120% given the pre-operative FOS is 100%.
30 minutes to 2 hours in recovery room
Number of return visits to the office or to the emergency room
Time Frame: 6 weeks
This information will be captured via the EMR or the patient questionnaires, at 2-days, 1-week and 6-weeks folow-up.
6 weeks
Cumulative number of days of catheterization
Time Frame: 6 weeks
Calculated from EMR at the 6-weeks post-operative visit.
6 weeks
Incidence of catheter acquired urinary tract infection (CAUTI)
Time Frame: 6 weeks
UTI is defined according to the CDC as a positive culture >10^5 CFU/ml with no more than 2 species of microorganisms in the patient's endorsing 1 or more UTI symptoms.
6 weeks
Time to discharge from PACU
Time Frame: 30 minutes to 2 hours in recovery room
Collected from EMR.
30 minutes to 2 hours in recovery room
Effectiveness of the sling procedure
Time Frame: 6 weeks
Incontinence severity index will be collected at enrollment and at 6 weeks post surgery. The score will be compared to determine if the procedure was effective at treating incontinence.
6 weeks
Postoperative pain
Time Frame: 6 weeks
Pain scale will be administered at 2-days, 1-week and 6-weeks follow-up.
6 weeks
Patient's expectation of postoperative recovery
Time Frame: Assessed at enrollment, average 10 minutes
Information will be collected via short survey at enrollment. The subject will be asked to assign a level of importance to post-operative factors such as pain control, prolonged catheterization, daily activities and ability to return to work.
Assessed at enrollment, average 10 minutes
Daily function postoperatively as well as satisfaction with the surgery
Time Frame: 6 weeks
Information will be gathered from questionnaires at 2-days, 1-week and 6-weeks follow-up. Modified validated questionnaire will be used (McCarthy et al).
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: John Eric Jelovsek, MD, The Cleveland Clinic
  • Study Director: Matthew Barber, MD, MHS, The Cleveland Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2011

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

April 26, 2011

First Submitted That Met QC Criteria

April 27, 2011

First Posted (Estimate)

April 28, 2011

Study Record Updates

Last Update Posted (Estimate)

February 19, 2014

Last Update Submitted That Met QC Criteria

February 18, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • IRB 11-082

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post-operative Voiding

Clinical Trials on Urinary voiding assessment after midurethral sling

3
Subscribe